Low expression of SLC22A18 predicts poor survival outcome in patients with breast cancer after surgery
Low expression of SLC22A18 predicts poor survival outcome in patients with breast cancer after surgery
复制标题
DOI：
10.1016/j.canep.2010.09.006
复制
发表时间：
2011-06-01
影响因子：
2.6
通讯作者：
Zhang, Hongwei
中科院分区：
文献类型：
--
作者：
He, Hongyu;Xu, Cheng;Zhang, Hongwei
目的：本研究的目的是评估SLC22A18表达与临床病理特征的关系，同时探讨SLC22A18表达在乳腺癌术后的预后价值。标本和方法：采用免疫组织化学方法检测乳腺肿瘤中SLC22A18蛋白的表达。评估SLC22A18蛋白和其他临床病理因素的预后价值。采用Kaplan-Meier法和Cox比例风险模型来预测具有显着独立预后价值的因素。采用数字图像分析来量化免疫染色。结果：SLC22A18 表达与肿瘤大小、淋巴结转移、临床分期和广泛的淋巴血管侵犯相关。 Kaplan-Meier分析结果表明SLC22A18表达与乳腺癌无复发生存（RFS）相关。高表达SLC22A18组的生存期与低表达组相比具有更长的生存期。差异显着（p = 0.003，对数秩检验）。 Cox回归分析显示肿瘤大小、淋巴结转移、核分期、广泛淋巴管侵犯和SLC22A18表达可能作为RFS的预后因素。核分期和SLC22A18表达是预测肿瘤复发最有意义的组织病理学参数。与SLC22A18高表达组相比，低表达组更容易复发。 HR 为 2.624 (p = 0.035)。结论：SLC22A18 的低表达与乳腺手术后肿瘤进展、复发和不良生存相关。检测SLC22A18的表达将有助于预测乳腺癌的预后。 Crown 版权所有 (C) 2010 由 Elsevier Ltd 出版。保留所有权利。
Purpose: The aims of this study were to evaluate the relationship between SLC22A18 expression and clinicopathologic features while investigate the prognostic value of SLC22A18 expression in breast cancer after surgery. Specimens and methods: Immunohistochemistry was used to examine SLC22A18 protein expression in the breast tumors. Prognostic value of SLC22A18 protein and other clinicopathologic factors were evaluated. The Kaplan-Meier method and the Cox proportional hazards model were used to predict factors with a significant independent prognostic value. Digital image analysis was employed to quantify immunostaining. Results: SLC22A18 expression was correlated with tumor size, lymph node metastasis, clinical stage, and extensive lyphovascular invasion. The results of Kaplan-Meier analysis indicated that SLC22A18 expression was associated with relapse-free survival (RFS) of breast cancer. The survival of higher expression SLC22A18 group had longer cum survival compared to the group with low expression. The difference was significant (p = 0.003, log-rank test). Cox's regression analysis showed that tumor size, lymph nodes metastasis, nuclear stage, extensive lymphovascular invasion, and SLC22A18 expression might be used as prognostic factor for RFS. Nuclear stage and SLC22A18 expression were the most meaningful histopathologic parameter in predicting tumor recurrence. Compared with the group of higher SLC22A18 expression, the lower expression group was more likely to relapse. The HR is 2.624 (p = 0.035). Conclusion: Low expression of SLC22A18 was associated with tumor progression, recurrence and poor survival after breast surgery. Testing expression of SLC22A18 will be helpful for predicting prognosis in breast cancer. Crown Copyright (C) 2010 Published by Elsevier Ltd. All rights reserved.